DV
Dividend Vision

ATYR — aTyr Pharma, Inc.

aTyr Pharma, Inc. (ATYR)

Total return is -99.7% over the past 11.3 years, 447.7 points behind SPY at 348.0%. Its deepest 1-year drawdown was 93.4%.

aTyr Pharma is a clinical-stage biotechnology company developing therapies based on tRNA synthetase biology, with its lead candidate efzofitimod in Phase 3 trials for pulmonary sarcoidosis and Phase 2 trials for other fibrotic and inflammatory lung diseases, along with earlier-stage programs targeting fibrosis and liver disorders. The company does not currently distribute dividends. aTyr Pharma appeals to investors seeking exposure to biotechnology development risk with a focus on rare and orphan fibrotic diseases.

ATYR key facts

Asset type
Stock
Asset class
Equity
Inception date
05/07/2015
Last close
$0.56
Market cap
$49,986,512
Average volume
656600.0
Beta
0.524
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.74